“Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s140. doi:10.25251/skin.7.supp.140.